[The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia].
In recent studies it was observed the pleiotropic properties beyond hypolipemic effects of fenofibrate: anti-inflammatory, antioxidants effects, positive impact on glucose metabolism, thrombosis, fibrinolytic system endothelial dysfunction.


OBJECTIVE
To estimate the effects of 4-weeks therapy of micronized fenofibrate in dose 267 mg/d on C-reactive protein (CRP), fibrinogen, thiobarbituric acid reaction substances (TBARS) concentrations in isolated erythrocyte membranes and the activities of antioxidants enzymes such: catalase (CAT), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) in erythrocytes in patients with visceral obesity and atherogenic dyslipidemia.


METHODS
The study comprised 55 patients (pts), including 20 healthy volunteers and 35 pts with visceral obesity and dyslipidemia (TG>180 mg/dl, HDL-C < 40 mg/dl for men, <50 mg/dl for women) treated with micronized fenofibrate (267 mg/d). Before and after 4 weeks of active treatment the following parameters were determined: lipids (by enzymatic method using BioMerieux tests), CRP (by immunoturbidimetric method), fibrinogen (by Clauss'a method), TBARS concentrations (by method of Stock and Dormandy), CAT (method of Bartosz et al.), GSH-Px (method of Rice-Evansa), SOD (method of Misra) activities.


RESULTS
It was noticed significantly higher concentrations of CRP fibrinogen, TBARS and lower activities of CAT GSH-Px, SOD in patients with visceral obesity and atherogenic dyslipidemia than in the control group. The micronized fenofibrate caused a significant decrease in serum total cholesterol (by 15%), TG (by 38%), CRP (by 35%), fibrinogen (by 26%) and TBARS (by 33%) concentrations associated with a increase in CAT (by 35%), GSH-Px (by 63%), SOD (by 31%) activities.


CONCLUSIONS
We conclude that micronized fenofibrate beyond hipolipemic efficacy demonstrates the antioxidative and anti-inflammatory properties in patients with visceral obesity and atherogenic dyslipidemia.
Broncel
Marlena
M
Uniwersytet Medyczny w Lodzi, Klinika Chorób Wewnetrznych z Oddziałem Farmakologii Klinicznej i Terapii Monitorowanej. ttm@ttm.org.pl
Cieślak
Dorota
D
Koter-Michalak
Maria
M
Duchnowicz
Piotr
P
Mackiewicz
Katarzyna
K
Chojnowska-Jezierska
Julita
J
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000975:Antioxidants / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000187:drug effects; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D004910:Erythrocyte Membrane / Q000201:enzymology; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage*; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D017392:Thiobarbituric Acid Reactive Substances; D005340:Fibrinogen; D002097:C-Reactive Protein; D011345:Fenofibrate